IPHYF Projected Dividend Yield

Shs Nom Cat A/Innate Pharma SA ( OTCBB : IPHYF )

Innate Pharma is a global, clinical-stage, oncology-focused biotech company focused on improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Co.'s product pipelines include: Lacutamab, which is for the treatment of certain subtypes of T-cell lymphoma; Monalizumab, which is an immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells; Avdoralimab, which is a monoclonal antibody blocking C5a binding to C5aR1; and IPH5301, which is a potential anticancer therapy for patients with advanced or metastatic disease in selected solid tumors.

20 YEAR PERFORMANCE RESULTS